June 26, 2026 01:11 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Amazon's massive India bet! Andy Jassy announces $48 billion investment after meeting PM Modi | Taratala warehouse collapse: Death toll climbs to 8, five arrested as SIT launches probe | Oil prices crash, IndiGo takes off! Aviation and fuel stocks emerge as biggest winners | Passport is a travel document, not conclusive proof of citizenship: MEA | Kolkata: Taratala warehouse roof collapses | Indian Army's Trishakti Corps restores lifeline connectivity in North Bengal between Siliguri and Mirik | 19 million barrels flow through Strait of Hormuz, Trump declares oil prices are falling | No Hindi, no NEET: Vijay reignites Tamil Nadu's biggest political flashpoints | Messi creates World Cup history with record-breaking double; Mbappe equals Klose's mark hours later | Tech giant Oracle slashes 21,000 jobs while betting big on AI
US Tariffs
A view inside a pharmacy’s automated medication storage facility. Photo: Jan Woitas/dpa-Zentralbild/dpa

US tariffs seen as threat to European pharma production, industry says

| @indiablooms | Apr 04, 2026, at 12:09 am

Pharmaceutical manufacturers in Germany and Switzerland on Friday warned that the latest US tariffs on pharmaceutical products could threaten production at their European facilities, industry representatives said.

"In the medium term, there is a risk that parts of production and research will move to the US," where regulatory and financial incentives are attractive, said the Association of Research-Based Pharmaceutical Companies (VFA) in Berlin.

The Swiss association Interpharma warned of negative consequences for patients.

The US administration seeks to encourage pharmaceutical companies to set up operations in the US by imposing a 100% surcharge.

However, Germany and all other EU member states, as well as Switzerland, Japan and South Korea, are exempt from this due to separate agreements. Tariff rates of up to 15% apply to them.

Nevertheless, the pharmaceutical associations view the new measures as a massive intervention in the medicines market.

The tariffs "jeopardise global production and supply chains for medicines, hinder research and development, and ultimately harm patients worldwide", Interpharma warned.

Individual manufacturers can avoid tariffs by increasing investment and production in the United States and by lowering their prices there.

Among others, the Swiss industry giants Novartis and Roche concluded agreements with the US government in December with this in mind.

Amid pressure from the US, investments in Germany are now also under scrutiny, VFA President Han Steutel said, adding that this makes it all the more important to develop a significant market in Europe as well.

He called for lower establishment costs, faster procedures and support for innovation.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.